Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Drugs for Non-Small Cell Lung Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Non-Small Cell Lung Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Non-Small Cell Lung Cancer Overall Market Size
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size: 2021 VS 2028
2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Non-Small Cell Lung Cancer Players in Global Market
3.2 Top Global Drugs for Non-Small Cell Lung Cancer Companies Ranked by Revenue
3.3 Global Drugs for Non-Small Cell Lung Cancer Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Non-Small Cell Lung Cancer Companies in Global Market, by Revenue in 2021
3.5 Global Companies Drugs for Non-Small Cell Lung Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Non-Small Cell Lung Cancer Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Non-Small Cell Lung Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Non-Small Cell Lung Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Drugs for Non-Small Cell Lung Cancer Market Size Markets, 2021 & 2028
4.1.2 Radiofrequency Ablation (RFA)
4.1.3 Radiation Therapy
4.1.4 Chemotherapy
4.1.5 Targeted Therapies
4.1.6 Immunotherapy
4.2 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue & Forecasts
4.2.1 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2022
4.2.2 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2023-2028
4.2.3 By Type - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Non-Small Cell Lung Cancer Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue & Forecasts
5.2.1 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2022
5.2.2 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2023-2028
5.2.3 By Application - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Drugs for Non-Small Cell Lung Cancer Market Size, 2021 & 2028
6.2 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue & Forecasts
6.2.1 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2022
6.2.2 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue, 2023-2028
6.2.3 By Region - Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2028
6.3.2 US Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.3.3 Canada Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.3.4 Mexico Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2028
6.4.2 Germany Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4.3 France Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4.4 U.K. Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4.5 Italy Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4.6 Russia Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4.7 Nordic Countries Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.4.8 Benelux Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2028
6.5.2 China Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.5.3 Japan Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.5.4 South Korea Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.5.5 Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.5.6 India Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2028
6.6.2 Brazil Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.6.3 Argentina Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Non-Small Cell Lung Cancer Revenue, 2017-2028
6.7.2 Turkey Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.7.3 Israel Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.7.4 Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
6.7.5 UAE Drugs for Non-Small Cell Lung Cancer Market Size, 2017-2028
7 Players Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Corporate Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.1.4 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.1.5 Bristol-Myers Squibb Key News
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Corporate Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.2.4 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.2.5 GlaxoSmithKline Key News
7.3 Menarini
7.3.1 Menarini Corporate Summary
7.3.2 Menarini Business Overview
7.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.3.4 Menarini Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.3.5 Menarini Key News
7.4 Sanofi
7.4.1 Sanofi Corporate Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.4.4 Sanofi Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.4.5 Sanofi Key News
7.5 Ziopharm Oncology
7.5.1 Ziopharm Oncology Corporate Summary
7.5.2 Ziopharm Oncology Business Overview
7.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.5.4 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.5.5 Ziopharm Oncology Key News
7.6 Alchemia
7.6.1 Alchemia Corporate Summary
7.6.2 Alchemia Business Overview
7.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.6.4 Alchemia Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.6.5 Alchemia Key News
7.7 Amgen
7.7.1 Amgen Corporate Summary
7.7.2 Amgen Business Overview
7.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.7.4 Amgen Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.7.5 Amgen Key News
7.8 Apotex
7.8.1 Apotex Corporate Summary
7.8.2 Apotex Business Overview
7.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.8.4 Apotex Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.8.5 Apotex Key News
7.9 BioMarin Pharmaceutical
7.9.1 BioMarin Pharmaceutical Corporate Summary
7.9.2 BioMarin Pharmaceutical Business Overview
7.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.9.4 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.9.5 BioMarin Pharmaceutical Key News
7.10 CellAct Pharma
7.10.1 CellAct Pharma Corporate Summary
7.10.2 CellAct Pharma Business Overview
7.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.10.4 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.10.5 CellAct Pharma Key News
7.11 Cerulean Pharma
7.11.1 Cerulean Pharma Corporate Summary
7.11.2 Cerulean Pharma Business Overview
7.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.11.4 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.11.5 Cerulean Pharma Key News
7.12 Cipla
7.12.1 Cipla Corporate Summary
7.12.2 Cipla Business Overview
7.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.12.4 Cipla Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.12.5 Cipla Key News
7.13 Cornerstone Pharmaceuticals
7.13.1 Cornerstone Pharmaceuticals Corporate Summary
7.13.2 Cornerstone Pharmaceuticals Business Overview
7.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.13.4 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.13.5 Cornerstone Pharmaceuticals Key News
7.14 Curis
7.14.1 Curis Corporate Summary
7.14.2 Curis Business Overview
7.14.3 Curis Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.14.4 Curis Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.14.5 Curis Key News
7.15 CytRx
7.15.1 CytRx Corporate Summary
7.15.2 CytRx Business Overview
7.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.15.4 CytRx Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.15.5 CytRx Key News
7.16 Eli Lilly
7.16.1 Eli Lilly Corporate Summary
7.16.2 Eli Lilly Business Overview
7.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.16.4 Eli Lilly Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.16.5 Eli Lilly Key News
7.17 Exelixis
7.17.1 Exelixis Corporate Summary
7.17.2 Exelixis Business Overview
7.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.17.4 Exelixis Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.17.5 Exelixis Key News
7.18 Fresenius Kabi
7.18.1 Fresenius Kabi Corporate Summary
7.18.2 Fresenius Kabi Business Overview
7.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.18.4 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.18.5 Fresenius Kabi Key News
7.19 Genentech
7.19.1 Genentech Corporate Summary
7.19.2 Genentech Business Overview
7.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.19.4 Genentech Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.19.5 Genentech Key News
7.20 Hikma Pharmaceuticals
7.20.1 Hikma Pharmaceuticals Corporate Summary
7.20.2 Hikma Pharmaceuticals Business Overview
7.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.20.4 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.20.5 Hikma Pharmaceuticals Key News
7.21 Hospira
7.21.1 Hospira Corporate Summary
7.21.2 Hospira Business Overview
7.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.21.4 Hospira Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.21.5 Hospira Key News
7.22 Intas Pharmaceuticals
7.22.1 Intas Pharmaceuticals Corporate Summary
7.22.2 Intas Pharmaceuticals Business Overview
7.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.22.4 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.22.5 Intas Pharmaceuticals Key News
7.23 Karyopharm Therapeutics
7.23.1 Karyopharm Therapeutics Corporate Summary
7.23.2 Karyopharm Therapeutics Business Overview
7.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.23.4 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.23.5 Karyopharm Therapeutics Key News
7.24 Kyowa Hakko Kirin
7.24.1 Kyowa Hakko Kirin Corporate Summary
7.24.2 Kyowa Hakko Kirin Business Overview
7.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.24.4 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.24.5 Kyowa Hakko Kirin Key News
7.25 Ligand Pharmaceuticals
7.25.1 Ligand Pharmaceuticals Corporate Summary
7.25.2 Ligand Pharmaceuticals Business Overview
7.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Major Product Offerings
7.25.4 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Revenue in Global Market (2017-2022)
7.25.5 Ligand Pharmaceuticals Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer